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Introduction: Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a 
primary goal of diabetes care, given its importance in obtaining a sustained reduction in micro-
vascular, and possibly macrovascular complications.
Aim: The aim of this review was to evaluate the clinical utility of a fixed dose combination of 
saxagliptin/metformin in the treatment of type 2 diabetes.
Evidence review: The combination of saxagliptin/metformin was well tolerated and pro-
duced sustained glycemic control for up to 76 weeks, with greater improvements in glycemic 
parameters compared with either drug alone. The saxagliptin/metformin combination also 
proved its non-inferiority compared with either sulfonylurea/metformin or sitagliptin/metformin 
combinations.
Place in therapy: Clinical practice recommends lifestyle interventions together with starting 
metformin at the time that the type 2 diabetes mellitus is diagnosed. Once metformin fails to 
maintain glycemic control, the addition of DPP-4 inhibitors should be the logical choice because 
of their effects on HbA1c compared to the addition of a sulfonylurea or glitazone, and because of 
their positive effects on beta cell function and their neutral effects on body weight. Furthermore, 
DPP-4 inhibitors prevent the risk of hypoglycemia posed by sulfonylureas.
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Introduction
Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a primary 
goal of diabetes care, given its importance in obtaining a sustained reduction in micro-
vascular, and possibly macrovascular complications.1 However, maintaining adequate 
metabolic control is still a challenge in many patients with type 2 diabetes mellitus 
(T2DM).2 Current guidelines from the American Diabetes Association/European 
Association for the Study of Diabetes (ADA/EASD) and American Association of 
Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) recom-
mend early initiation of combination therapy with oral antidiabetic drugs in patients 
with HbA1c . 8.5% and 7.6%–9.0%, respectively.1,3 In particular metformin is recom-
mended (unless specifically contraindicated) as a first-line agent for monotherapy and 
combination therapy for patients with T2DM. This recommendation is based primarily 
on metformin’s glucose-lowering effects, absence of weight gain, generally low level 
of side effects, and relatively low cost.1,3
While monotherapy with oral antidiabetic drugs may be effective in improving 
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required for long-term control because of the progressive 
loss of β-cell function and increase in insulin resistance.4 
In this regard, recent breakthroughs in the understanding of 
incretin-based therapies have provided additional options 
for the treatment of T2DM. Incretins are gastrointestinal 
hormones released during nutrient absorption to increase 
insulin secretion. The two gut peptides accounting for most 
of the incretin effect are glucagon-like peptide 1 (GLP-1) and 
glucose-dependent insulinotropic peptide (GIP). In response 
to a meal, GLP-1 and GIP are released and, in turn, stimulate 
insulin (both in a glucose-dependent manner), delay gastric 
emptying, and increase satiety.5,6 Furthermore, GLP-1 acts on 
alpha cells and inhibits the secretion of glucagons.7 Within 
some minutes of release from their intestinal sites, GIP and 
GLP-1 undergo rapid metabolism (proteolytic cleavage) to 
inactive metabolites by the enzyme dipeptidyl peptidase-4 
(DPP-4). In T2DM, GLP-1 concentrations are reduced in 
response to a meal, whereas GIP concentrations are normal 
or increased. This observation suggests resistance to the 
action of GIP, making GLP-1 the favored potential thera-
peutic target.8
Because GLP-1 is rapidly degraded by DPP-4,9 a new 
class of compounds have been developed: DPP-4 inhibi-
tors, that delay endogenous degradation of GLP-1 and GIP. 
  Inhibition of the proteolytic DPP-4 enzyme results in a 
two- to three-fold increase in circulating levels of GLP-1 
and GIP, suppressing glucagon secretion in the post-prandial 
state, stimulating glucose dependent insulin secretion from 
pancreatic β-cells,10–12 and decreasing hepatic glucose pro-
duction in the fasting state, thereby reducing both fasting 
plasma glucose (FPG) and post-prandial glucose (PPG).4,13 
The first DPP-4 inhibitor released for use in clinical practice 
was sitagliptin, followed by vildagliptin and saxagliptin. 
Sitagliptin received US Food and Drug Administration 
approval in October 2006 and received European Medicines 
Agency approval in March 2007. It is licensed at the recom-
mended dose of 100 mg once daily either as monotherapy 
or in combination. As monotherapy, the indication in the 
US is as an adjunct to diet and exercise to improve gly-
cemic control in patients with T2DM, whereas in the EU, 
sitagliptin is indicated as monotherapy in patients who have 
inadequate glycemic control with diet and exercise and in 
whom metformin is inappropriate due to contraindications 
or intolerance. Sitagliptin is also indicated, both in the 
US and in EU, in combination therapy with metformin, a 
sulfonylurea, or a thiazolidinedione in patients who have 
inadequate control with these agents used as single agents 
plus diet and exercise. Recently, sitagliptin was also approved 
to be used in combination with insulin. Sitagliptin is also 
indicated as a triple therapy in   combination with metformin 
plus a sulfonylurea, or metformin plus a thiazolidinedione, 
in patients who have inadequate glycemic control with the 
two agents (Table 1).14 Vildagliptin was approved by the 
European Medicines Agency in July 2007 and it is licensed at 
the recommended dose of 50 mg twice a day in combination 
with either metformin or sulfonylureas or thiazolidinediones 
in patients poorly controlled on the maximum doses of these 
drugs (Table 1).15 Saxagliptin, the last addition to the family 
of DPP-4 inhibitors, is administered at the recommended dose 
of 5 mg once daily in combination with metformin, or sulfo-
nylureas or a thiazolidinedione (Table 1).15 The mechanism 
of action of the DPP-4 inhibitors is complementary to that of 
metformin, which improves insulin sensitivity and reduces 
hepatic glucose production,12 for this reason this combina-
tion can be very useful in the clinical practice, to achieve an 
adequate glycemic control. The aim of this review was to 
evaluate the clinical utility of a fixed dose combination of 
saxagliptin/metformin in the treatment of type 2 diabetes.
Material and methods
A systematic search strategy was developed to identify 
randomized controlled trials in both MEDLINE (National 
Library of Medicine, Bethesda, MD; 1996 through March 
2011) and the Cochrane Register of Controlled Trials 
(The Cochrane Collaboration, Oxford, United Kingdom). 
The terms “DPP-4 inhibitors”, “saxagliptin”, “metformin”, 
“combination saxagliptin/metformin”, “fixed dose of 
saxagliptin/metformin” were incorporated into an elec-
tronic search strategy that included the Dickersin filter for 
randomized controlled trials.16 It was also discovered that 
some reports have only been published in languages other 
than English. To avoid problems and limitations with the 
translation of these reports, it was decided to perform this 
review by including only studies published in English. 
The bibliographies of all identified randomized trials and 
review articles were reviewed to look for additional studies 
of interest. We subsequently reviewed the potential trials to 
determine their eligibility. To qualify for inclusion, clinical 
trials were required to be randomized trials comparing a 
fixed dose of saxagliptin/metformin combination with any 
other oral antidiabetic drug in type 2 diabetic patients. Eli-
gible trials had to present results on glycemic control, insulin 
resistance, insulin sensitivity and adverse events. Two dif-
ferent outcomes related to glycemic control improvement 
were of primary interest: (1) the proportion of individuals 
within each treatment group achieving   clinically   significant Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 DPP-4 agonists: dosage and use
Drug Dosage Use
Sitagliptin 100 mg once daily As an adjunct to diet and exercise to improve glycemic control as an add-on therapy to:
• metformin (dual therapy)
• sulfonylurea (dual therapy)
• pioglitazone (dual therapy)
• sulfonylurea plus metformin (triple therapy)
• pioglitazone plus metformin (triple therapy)
•   In the US as monotherapy; in the EU as monotherapy in patients in whom metformin is 
inappropriate due to contraindications or intolerance
• Insulin (with or without metformin)
Vildagliptin 50 mg twice daily As an adjunct to diet and exercise to improve glycemic control as an add-on therapy to:
• metformin (dual therapy)
• sulfonylurea (dual therapy): in that case vildagliptin should be used at the dosage of 50 mg/day
• pioglitazone (dual therapy)
Saxagliptin 5 mg once daily As an adjunct to diet and exercise to improve glycemic control as an add-on therapy to:
• metformin (dual therapy)
• sulfonylurea (dual therapy)
• pioglitazone (dual therapy)
HbA1c   reduction, and (2) the mean amount decrease (in%) 
within each treatment group. Variations in insulin resis-
tance and insulin sensitivity that occurred during various 
trials were secondary outcomes of interest, as was the fre-
quency of patients having one or more adverse events such 
as   hypoglycemia. A validated, 3-item scale was used to 
evaluate the overall reporting quality of the trials selected 
for inclusion in the present review. This scale provided 
scoring for randomization (0–2 points), double-blinding 
(0–2 points), and account for withdrawals (1 point). Scores 
ranged between 0 and 5. A score above 3 indicated a study 
of high quality and study selection was restricted to random-
ized controlled trials to ensure the inclusion of only high 
quality evidence.17
Chemical structure, including  
key PK/PD data
Saxagliptin (BMS-477118; (S)-3 hydroxyadamantylglycine-
L-cis-4,5 methanoprolinenitrile) is a nitrile-containing 
DPP-4 inhibitor, with the molecular formula C18H27N3O3 
and a molecular weight of 333.4 Da. It is a potent inhibi-
tor of DPP-4 (inhibition constant, Ki = 0.6–1.3 nM) that 
displays slow-binding properties. Thus, kinetic studies have 
suggested that inhibition of DPP-4 by saxagliptin is a two-
step process that involves formation of a reversible covalent 
enzyme inhibitor complex, in which there is a slow onset of 
inhibition and a slow rate of inhibitor dissociation, resulting 
in the enzyme slowly equilibrating between the active and 
inactive forms.18,19  Metformin hydrochloride (N,N-dimethy-
limidodicarbonimidic diamide hydrochloride) is a white to 
off-white crystalline compound with a molecular formula 
of C4H11N5HCl and a molecular weight of 165.63 Da. 
Metformin hydrochloride is freely soluble in water and is 
practically insoluble in acetone, ether, and chloroform. The 
pKa of metformin is 12.4. The pH of a 1% aqueous solution 
of metformin hydrochloride is 6.68.
Efficacy studies with saxagliptin/
metformin
For a summary of the following studies, see Table 2.
Saxagliptin/metformin as initial therapy
Pfützner et al assessed the efficacy and safety of saxa-
gliptin/metformin combination therapy compared with 
saxagliptin or metformin alone over 24 and 76 weeks in 
treatment-naive T2DM patients with inadequate glycemic 
control.20,21 One thousand, three hundred and six patients, 
18–77 years of age (HbA1c 8.0%–12.0%), were randomized 
to saxagliptin/metformin 5/500 mg, saxagliptin/metformin 
10/500 mg, 10 mg saxagliptin/placebo or 500 mg met-
formin/placebo. At week 76, adjusted mean changes (95% 
CI) from baseline HbA1c were −2.31% (−2.44, −2.18) for 
saxagliptin/metformin 5/500 mg, −2.33% (−2.46, −2.20) 
for saxagliptin/metformin 10/500 mg, −1.55% (−1.70, 
−1.40) for saxagliptin 10 mg and −1.79% (−1.93, −1.65) for 
metformin 500 mg (P , 0.0001 versus metformin and saxa-
gliptin monotherapies for saxagliptin/metformin 5/500 mg 
and saxagliptin/metformin 10/500 mg). A higher proportion 
of patients achieved a HbA1c , 7% at week 76 with saxa-
gliptin/metformin 5/500 mg and saxagliptin/metformin Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 2 summary of the studies included in the review
Study Duration Drugs involved Baseline population Results
Pfützner et al20,21 76 weeks
• saxagliptin/metformin 5/500 mg
• saxagliptin/metformin 10/500 mg
• saxagliptin 10 g/placebo
• metformin 500 mg/placebo.
1306 patients, 18–77 years of  
age with HbA1c 8.0%–12.0%.
HbA1c: 
•   −2.31% for saxagliptin/metformin  
5/500 mg*
•   −2.33% for saxagliptin/metformin  
10/500 mg*
• −1.55% for saxagliptin 10 mg
•   −1.79% for metformin 500 mg 
(*P , 0.0001 versus metformin  
and saxagliptin monotherapies)
Scheen et al22 18 weeks
•   saxagliptin 5 mg once daily  
as add on therapy to 
previously taken metformin
801 patients with HbA1c between 
6.5%–10% on stable metformin  
doses (1500–3000 mg/day).
HbA1c: 
• −0.52% for saxagliptin/metformin
•   sitagliptin 100 mg once daily  
as add-on therapy to previously  
taken metformin.
•   −0.62% for sitagliptin/metformin  
(P not significant)
De Fronzo et al23 24 weeks
•   saxagliptin 2.5 mg once daily  
as add on therapy to previously 
taken metformin
743 patients taking a stable dose  
of metformin (1.500 but  
not .2.550 mg/day)
HbA1c: 
•   −0.59% for saxagliptin  
2.5 mg/metformin*
•   saxagliptin 5 mg once daily  
as add on therapy to previously  
taken metformin
• −0.69% for saxagliptin 
 5 mg/metformin*
•   saxagliptin 10 mg once daily  
as add on therapy to previously  
taken metformin
•   −0.58% for saxagliptin 
10 mg/metformin*
•   placebo as add on therapy  
to previously taken metformin.
•   +0.13% for placebo/metformin  
(*P # 0.0001 versus placebo)
Goke et al24 52 weeks
•   saxagliptin 5 mg once daily  
as add on therapy to previously  
taken metformin
858 patients on stable metformin  
doses $1500 mg/day
HbA1c: 
• −0.74% for saxagliptin/metformin
•   −0.80% for glipizide/metformin  
(P not significant)
•   glipizide up-titrated as needed  
from 5 to 20 mg/day as add  
on therapy to previously  
taken metformin.
Hypoglycemia:
• 3% for saxagliptin/metformin*
•   36.3% for glipizide/metformin  
(*P , 0.0001 versus glipizide/metformin)
Body weight: 
• −1.1 kg for saxagliptin/metformin*
•   +1.1 kg for with glipizide/metformin  
(*P , 0.0001 versus glipizide/metformin)
10/500 mg than with either agent alone. Similarly, a higher 
proportion of patients achieved a HbA1c , 6.5% at week 76 
with saxagliptin/metformin 5/500 mg and saxagliptin/met-
formin 10/500 mg than with either agent alone. For FPG at 
week 76, saxagliptin/metformin 5/500 mg and saxagliptin/
metformin 10/500 mg groups had similar results (−54 ± 2.6 
and −55 ± 2.6 mg/dL, respectively), while changes for the 
monotherapy groups were smaller (−24 ± 3.0 mg/dL for 
saxagliptin 10 mg and −40 ± 2.8 mg/dL for metformin). 
For post-prandial glucose (PPG) at week 76, adjusted mean 
decrease from baseline was: −137 ± 5.6 mg/dL with saxaglip-
tin/metformin 5/500 mg; −129 ± 5.9 mg/dL with saxagliptin/
metformin 10/500 mg; −94 ± 6.6 mg/dL with saxagliptin 
monotherapy; and −86 ± 5.9 mg/dL with metformin/ 
placebo. Changes with saxagliptin/metformin combination 
were greater than either monotherapy. Small decreases in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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mean body weight were observed in all treatment groups. 
The safety profile was similar across treatment groups: in 
particular the overall frequency of hypoglycemic events was 
low (4.7% with saxagliptin/metformin 5/500 mg, 6.8% with 
saxagliptin/metformin 10/500 mg, 2.1% with saxagliptin 
10 mg, and 6.1% with metformin alone).
Saxagliptin as add-on therapy  
to metformin
Scheen et al compared the efficacy of saxagliptin in 
combination with metformin compared with sitagliptin 
in   combination with metformin in 801 patients with 
HbA1c between 6.5%–10% on stable metformin doses 
(1500–3000 mg/day).22 Patients were randomized to 
add-on 5 mg saxagliptin or 100 mg sitagliptin once daily 
for 18 weeks. The addition of saxagliptin or sitagliptin to 
metformin therapy produced similar decreases in mean 
HbA1c from baseline to week 18. Mean HbA1c declined 
from 7.68 to 7.16% in the saxagliptin/metformin group; 
the adjusted mean ± SE change was −0.52% ± 0.039 
(95% CI, −0.60 to −0.45%). Similarly, mean HbA1c 
declined from 7.69 to 7.07% in the sitagliptin/metformin 
group, an adjusted mean change of −0.62% ± 0.038 
(95% CI, −0.69 to −0.54%). The proportion of patients 
achieving therapeutic glycemic responses was similar in 
the two treatment groups. Overall, 105 of 399 patients 
(26.3%) who received saxagliptin/metformin compared 
with 114 of 392 patients (29.1%) who received sitagliptin/
metformin achieved a HbA1c # 6.5% at week 18. For 
those with a HbA1c $ 7.0% at baseline, 97 of 294 patients 
(33.0%) in the saxagliptin/metformin group and 117 of 
299 patients (39.1%) in the sitagliptin/metformin group 
achieved a HbA1c , 7.0% at week 18, a −6.1% difference 
between groups (95% CI,−13.8 to 1.6%). Improvements in 
glycemic control were also observed as decreases in FPG 
from baseline to week 18. Adding saxagliptin or sitagliptin 
to metformin therapy produced adjusted mean changes in 
FPG of −0.60 mmol/L (−10.8 mg/dL) and −0.90 mmol/L 
(−16.2 mg/dL), respectively. The mean difference was 
0.30 mmol/L (5.42 mg/dL); 95% CI, 0.08–0.53 mmol/L 
(1.37–9.47 mg/dL). There were no apparent differences 
between treatment groups for the changes from baseline 
in fasting insulin, glucagon, proinsulin, or C-peptide. 
Similarly, the small improvement in β-cell function, as 
measured by the change from baseline in homeostasis model 
assessment-2β (HOMA-2β), did not differ between the two 
treatment groups. The safety profile of the two combinations 
was   similar: in particular, hypoglycemic adverse events 
occurred in 13 patients (3.2%) in the saxagliptin/metformin 
group and in 11 patients (2.8%) in the sitagliptin/metformin 
group.
De Fronzo et al23 evaluated the efficacy of combi-
nation of saxagliptin added to metformin compared to 
metformin alone in a 24-week randomized, double-blind, 
placebo-controlled trial. Seven hundred and forty three patients 
taking a stable dose of metformin (1.500 but not . 2.550 mg/
day) for at least 8 weeks before screening, were randomized 
to add 2.5, 5, or 10 mg saxagliptin or   placebo for 24 weeks in 
addition to their lead-in dose of open-label metformin.23 At week 
24, treatment with saxagliptin led to clinically and statistically 
significant reductions in HbA1c from baseline   versus metformin/
placebo. Differences in adjusted mean change from baseline 
versus placebo (95% CI) were −0.73% (−0.92 to −0.53) for the 
combination 2.5 mg saxagliptin/metformin, −0.83% (−1.02 
to −0.63) for the combination 5 mg saxagliptin/metformin, 
and −0.72% (−0.91 to −0.52) for the combination 10 mg 
saxagliptin/metformin, respectively (all P , 0.0001). Glycated 
hemoglobin reductions relative to metformin/placebo occurred 
in all saxagliptin treatment groups by week 4, the earliest time 
point assessed. Maximal HbA1c reductions were reached at 12 
weeks and were sustained through 24 weeks. The percentage 
of patients achieving HbA1c , 7.0% was comparable for 5 and 
10 mg saxagliptin and higher than that for 2.5 mg saxagliptin. 
A greater percentage of patients taking saxagliptin achieved 
HbA1c , 7.0% versus those taking metformin/placebo. The 
differences from metformin/placebo (95% CI) were: 20.5% 
(10.6–30.5) for the combination 2.5 mg saxagliptin/metformin; 
27.0% (17.0–36.7) for the combination 5 mg saxagliptin/
metformin; and 27.9% (17.7–37.7) for the combination 10 mg 
saxagliptin/metformin, respectively (all P , 0.0001). Statisti-
cally significant FPG reductions at week 24 were observed in 
all saxagliptin treatment groups versus the metformin/placebo 
group (P , 0.0001). Differences in adjusted mean change from 
baseline versus metformin/placebo (95% CI) were:-15.6 mg/
dL (−22.5 to −8.5) for the combination 2.5 mg saxagliptin/
metformin; −23.3 mg/dL (−30.3 to −16.3) for the combina-
tion 5 mg saxagliptin/metformin; and −21.7 mg/dL (−28.8 
to −14.7) for the combination 10 mg saxagliptin/metformin, 
respectively. Differences between the effects of saxagliptin 
and metformin/placebo on mean FPG were apparent and near 
maximal as early as week 2 in all saxagliptin treatment groups, 
with the effect maintained throughout 24 weeks. The early 
insulin response based on the insulinogenic index, and insulin 
sensitivity, increased in all saxagliptin treatment groups at week 
24. The overall frequency of confirmed hypoglycemia during 
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patients (0.5%) and metformin/placebo-treated patients (0.6%). 
No dose relationship was observed among the three saxagliptin 
groups.
Goke et al assessed the efficacy and safety of saxaglip-
tin compared to glipizide as add-on therapy to metformin 
in patients with type 2 diabetes mellitus and inadequate 
  glycemic control on metformin alone.24 A total of 858 patients 
on stable metformin doses $1500 mg/day were randomised 
to saxagliptin 5 mg/day or glipizide up-titrated as needed 
from 5 to 20 mg/day for 52 weeks. At 52 weeks, saxagliptin/
metformin was non-inferior to glipizide/metformin in 
lowering HbA1c. Adjusted mean changes from baseline 
HbA1c were −0.74% with saxagliptin/metformin and −0.80% 
glipizide/metformin, respectively; the between-group differ-
ence was 0.06% (95% CI 0.05% to 0.16%). The proportion 
of patients reporting $ 1 hypoglycemic event over 52 weeks 
was low in the saxagliptin/metformin group (3.0%), and was 
significantly lower compared with the glipizide/metformin 
group (36.3%) (difference versus glipizide/metformin 
−33.2% (95% CI, −38.1% to −28.5%; P , 0.0001). Treatment 
with saxagliptin was associated with an adjusted mean change 
in body weight from baseline of −1.1 kg with saxagliptin 
and +1.1 kg, with glipizide, respectively; the between-group 
difference was −2.2 kg (95% CI, −2.7 to −1.7; P , 0.0001). 
There was a small rise per week in HbA1c during weeks 
24–52 in both treatment groups (mean changes per week 
0.001% for saxagliptin and 0.004% for glipizide). The rise per 
week was statistically significantly smaller with saxagliptin 
versus glipizide (−0.002% difference, 95% CI, −0.0046% 
to −0.0001%; P = 0.04) indicating a more sustained effect 
on glycemic control beyond week 24. There were small 
and generally similar increases from baseline in both treat-
ment groups in mean values for fasting insulin and fasting 
C-peptide. Numerical reductions in fasting proinsulin (mean 
difference versus glipizide/metformin −5.5 ± 1.67) and 
numerically smaller increases in fasting glucagon (mean 
difference versus   glipizide/metformin −4.9 ± 1.88) were 
demonstrated for saxagliptin versus glipizide. Patients treated 
with glipizide/metformin had a greater mean increase in 
HOMA-2β (+21.7 ± 2.56) versus saxagliptin/metformin 
(+7.4 ± 2.54).
Safety and tolerability
Generally, saxagliptin has been reported to be well tolerated 
in clinical studies. The most common adverse events reported 
in patients receiving combination therapy and occurring 
more commonly than with metformin alone included 
headache (7.5% versus 5.2%), nasopharyngitis (6.9% versus 
4.0%), upper respiratory tract infection, and urinary tract 
infection.25
Coadministration of strong cytochrome P 450 isoenzyme 
3 A4/5 inhibitors (eg, ketoconazole) significantly increases 
saxagliptin concentrations, necessitating dose limitations to 
2.5 mg/1000 mg once daily. Lower doses of concomitantly 
administered sulfonylureas may be needed to reduce the risk 
for saxagliptin-related hypoglycemia. 
Metformin-related adverse events include diarrhea and 
nausea/vomiting; because of the metformin-related risk for 
lactic acidosis, patients should be warned against excessive 
alcohol intake. Treatment with saxagliptin/metformin is not 
recommended in hepatic impairment and contraindicated 
in renal impairment. Renal function should be monitored 
before initiation of therapy and at least annually thereafter; 
more frequent assessments are recommended for patients 
at risk of renal impairment, such as the elderly. Treatment 
should be temporarily discontinued in patients undergoing 
radiologic studies with intravascularly administered iodinated 
contrast materials, and those undergoing surgical procedures 
associated with restricted intake of food and fluids.
Hypoglycemia
Hypoglycemia was reported in 3.4% of treatment-naive 
patients receiving saxagliptin 5 mg/metformin combination 
therapy compared with 4.0% of those receiving metformin 
alone. Among treatment-experienced patients, the incidence of 
reported hypoglycemia for saxagliptin 2.5 mg and   saxagliptin 
5 mg with metformin was 7.8% and 5.8%, respectively, com-
pared with 5.0% for those receiving   metformin monotherapy.
Compared to the sulfonylureas, saxagliptin gave a low 
incidence of hypoglycemia, as reported by Goke et al.24 Three 
percent of patients in the saxagliptin/metformin group and 
36.3% of patients in the glipizide/metformin group experienced 
hypoglycemic events over the 52-week treatment period. Most 
hypoglycemic events were mild in intensity; 0.2% of patients 
in the saxagliptin/metformin group and 14.4% of patients in 
the glipizide/metformin group had hypoglycemic events that 
were moderate in intensity. No patients in the saxagliptin/met-
formin group and 1.6% of patients in the glipizide/metformin 
group had hypoglycemic events that were severe. No patients 
in the saxagliptin/metformin group and 0.9% of patients in the 
  glipizide/metformin group experienced a mild hypoglycemic 
adverse event requiring medical assistance.
Patient perspectives
In November 2010, the US Food and Drug Administration 
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tablet featuring saxagliptin and extended-release (XR) 
  metformin HCl to improve glycemic control in adults 
with type 2 diabetes mellitus. Saxagliptin/metformin 
XR is   available in 5 mg/500 mg, 5 mg/1000 mg, and 
2.5 mg/1000 mg strengths. The starting dose should be 
individualized based on the patient’s current regimen and 
administered with the evening meal, with gradual dose titra-
tion to decrease the risk for metformin-related gastrointestinal 
events (maximum dose, 5 mg/2000 mg). This prescription 
provides good acceptability for patients with T2DM, who 
are commonly treated with a large number of drugs. This 
fixed dose combination also allows physicians to increase 
the antidiabetic therapy in patients not well controlled by 
metformin alone without increasing the number of pills 
taken by the patients, improving patient compliance. The 
combination of saxagliptin/metformin proved to be safer 
than combinations of sulfonylureas/metformin with respect 
to hypoglycemic events.24 This aspect is very important: 
hypoglycemia can be very dangerous in patients with coro-
nary disease because of the risk of triggering a heart attack, 
and in older people because of the risk of falls. Also, the 
saxagliptin/metformin combination proved to be neutral or 
even positive with respect to body weight gain, and this is 
another advantage of this combination.24
Conclusion and place in therapy
The studies reported above showed that the combination 
of saxagliptin/metformin was well tolerated and produced 
sustained glycemic control for up to 76 weeks, with greater 
improvements in glycemic parameters when compared 
with either drug alone.20 These results are generally simi-
lar to those obtained with the other two DPP-4 inhibitors, 
sitagliptin26,27 and vildagliptin.28 At 1 year, the least squares 
reduction from baseline results of HbA1c was greater for 
sitagliptin/metformin 100/2000 mg (−1.9%) than for met-
formin 2000 mg alone (−1.6%).26 At 2 years, the initial 
combination reduction (−1.7%) remained greater than that 
for metformin alone (−1.3%). Other glycemic measures were 
consistent with the HbA1c results.27 For vildagliptin, there 
was a 24 week study which compared vildagliptin combined 
with high-dose metformin combination therapy (50/1000 mg 
twice daily), vildagliptin combined with low-dose metformin 
combination therapy (50/500 mg twice daily), vildagliptin 
monotherapy (50 mg twice daily) and high-dose metformin 
monotherapy (1000 mg twice daily).28 From comparable 
baseline values (8.6%–8.7%), HbA1c decreased in all four 
treatment groups, to the greatest extent with vildagliptin/
metformin 50/1000 mg twice daily. Mean HbA1c change from 
baseline was: −1.8% ± 0.06% with vildagliptin/metformin 
50/1000 mg twice daily; −1.6% ± 0.06% with vildagliptin/ 
metformin 50/500 mg twice daily; −1.1% ± 0.06% 
with   vildagliptin monotherapy (50 mg twice daily); 
and −1.4% ± 0.06% with high-dose metformin   monotherapy 
(1000 mg twice daily). The between-group   difference was 
superior with vildagliptin/metformin 50/1000 mg twice daily 
combination therapy (P , 0.001 versus both monotherapies) 
and vildagliptin/metformin 50/500 mg twice daily combina-
tion therapy (P , 0.001 and P = 0.004, versus vildagliptin 
and metformin monotherapies, respectively). There was no 
incidence of hypoglycemia or severe hypoglycemia with 
either combination therapy, and neither was associated 
with weight gain. All treatments were well tolerated and 
displayed a comparable incidence of adverse events overall. 
Our group29 conducted a study on sitagliptin, where we 
compared sitagliptin/pioglitazone 100/30 mg once a day 
and metformin/pioglitazone 850/15 mg twice a day. After 
12 months of treatment we showed that the addition of either 
sitagliptin or metformin to pioglitazone gave an improvement 
in HbA1c, FPG, and PPG; but metformin led also to a decrease 
in body weight and to a faster and better improvement of 
insulin resistance and inflammatory state parameters, even 
if sitagliptin gave a better protection of beta-cell function.29 
We have also conducted a study on vildagliptin comparing 
either pioglitazone 30 mg once a day plus vildagliptin 50 mg 
twice a day or glimepiride 2 mg 3 times a day plus vildagliptin 
50 mg twice a day. We observed that, after 12 months, the 
pioglitazone/vildagliptin combination was more effective 
in preserving beta-cell function, and in reducing insulin 
resistance and inflammatory state parameters than vildaglip-
tin/glimepiride.30 The positive effect on insulin resistance is 
very important given that the main mechanism of T2DM is 
insulin resistance.
When directly compared to other DPP-4 inhibitors such 
as sitagliptin, saxagliptin showed its non-inferiority when 
added to metformin therapy in lowering HbA1c. Saxagliptin 
was generally well tolerated in patients with T2DM whose 
glycemia was inadequately controlled by metformin alone.19 
Saxagliptin proved also its non-inferiority compared to 
sulfonylureas in the study conducted by Goke et al where 
saxagliptin/metformin combination was well tolerated, pro-
vided a sustained HbA1c reduction over 52 weeks, reduced 
body weight and a significantly lower risk of hypoglycemia.24 
  Furthermore, patients treated with glipizide plus metformin 
had a greater mean increase in HOMA-2β, proving once 
again the protective effect of DPP-4 inhibitors, and in 
particular saxagliptin, on β-cell.24Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Clinical practice recommendations for the treatment of 
T2DM advocate lifestyle interventions (dietary modification, 
increased exercise, weight loss) together with starting 
metformin treatment at the time that the T2DM is   diagnosed.1 
Once metformin fails to maintain glycemic control 
another antidiabetic drug should be added. In this setting, 
DPP-4 inhibitors should be the logical choice because of 
their comparable effects on HbA1c compared to the addition 
of a sulfonylurea31,32 or glitazone,33,34 and because of their 
positive effects on beta cell function and their neutral effects 
on body weight. DPP-4 inhibitors are particularly indicated 
in young patients, with a long life expectancy, because of 
the protective effect on β-cell function. While sulfonylu-
reas increase HOMA-2β and proinsulin,24 DPP-4 inhibi-
tors reduce them, granting a longer survival of β-cells.29 
DPP-4 inhibitors also reduce insulin resistance, decreasing 
HOMA-IR,29,30 and they also prevent the risk of hypoglyce-
mia posed by sulfonylureas. This makes these drugs safer 
in elderly patients.35
In summary
•	 When diet and exercise are not enough to produce 
adequate glycemic control, metformin should be added
•	 When diet, exercise, and metformin are not enough, 
a combination therapy should be started. DPP-4 inhibitors 
could be a good choice
•	 DPP-4 inhibitors, and in particular saxagliptin, showed 
their non-inferiority compared to sulfonylureas in 
improving HbA1c
•	 DPP-4 inhibitors, in particular saxagliptin, gave a 
lower incidence of hypoglycemic events compared to 
sulfonylureas
•	 The combination of saxagliptin/metformin proved to have 
a positive effect on body weight.
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